Why Novo Nordisk A/S’s (NVO) Stock Is Up 7.13%
As of Wednesday, November 04, Novo Nordisk A/S’s NVO share price has surged by 7.13%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Cynthia McLaughlin
Cynthia McLaughlin
Rosalio Madrigal
Jenna Brashear
| Share Statistics | NVO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $178,607.0 | $436.9 | 99% |
|
| Shares Out (Mil) | 672.1 | 46.5 | 91% |
|
| Institutional Ownership | 100.0% | 82.2% | 99% |
|
| Float (Mil) | 3,155.7 | 47.7 | 97% |
|
| Beta | 0.37 | 0.68 | 20% |
|
| Avg Daily Volume (000s) | 14,542 | 339 | 97% |
|
| Price Change (52-week) |
(15.7%) | 52.1% | 39% |
|
| Growth | NVO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 18.4% | 6.6% | 79% |
|
| Net Income (5yr) | 18.4% | (1.6%) | 71% |
|
| EPS (5yr) | 19.6% | 15.1% | 68 |
|
| Dividends (5yr) | 19.7% | 0.0% | 88% |
|
| Cash Flow (5yr) | 41.0% | (15.1%) | 91% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 8 | 9 | |
| Current EPS | $0.718 | $3.487 | $3.444 | |
| Month Ago EPS | $0.636 | $3.301 | $3.374 | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | $0.653 | $3.400 | $3.240 | |
| Year/Year Chg | 24.7% | (3.7%) | 7.0% | |
| Financials | NVO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $50,700 | $289 | 97% |
|
| Net Income (TTM) (Mil) | $17,198 | ($11) | 99% |
|
| EPS (TTM) | $3.879 | ($0.600) | 82% |
|
| Operating Cash Flow (TTM) (Mil) | $19,348 | ($7) | 99% |
|
| Net Cash Flow (TTM) (Mil) | $1,812 | $1 | 97% |
|
| Long-Term Debt (Q1) (Mil) | $17,892 | $6 | 95% |
|
| Enterprise Value (Q1) (Mil) | $199,956 | $331 | 98% |
|
| Valuation | NVO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.42 | 2.15 | 83% |
|
| P/E | 10.5 | 24.2 | 22% |
|
| Dividend Yield | 2.8% | 0.0% | 82% |
|
| PEG (5yr hist) | 0.5 | 1.2 | 28% |
|
| Ratios | NVO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 83.3% | 69.5% | 90% |
|
| Net Margin | 33.9% | 3.6% | 91% |
|
| ROA | 20.1% | (23.3%) | 96% |
|
| ROE | 57.5% | (24.7%) | 94% |
|
| Liabilities to Assets | 63.6% | 31.8% | 59% |
|
| F-Score | 7 | 3 | 82% |
|
Novo Nordisk A/S did not pass any screens on 11/17/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors